Genetic Testing Innovator GeneLink BioSciences, Inc. Announces the Appointment of Dr. Bernard L. Kasten as Executive Chairman

JERSEY CITY, NJ – (Business Wire) – July 11th, 2007– GeneLink BioSciences, Inc. (OTCBB: GNLK) a pioneer in personalized nutritional and skincare products, announces the appointment of Dr. Bernard L. Kasten as Executive Chairman of the Board. A Clinical Pathologist, Dr. Kasten has previously served as a Scientific Advisor for GeneLink.  

Leveraging his experience as the former Chief Laboratory Officer of Quest Diagnostics, (DGX:NYSE) and his years as a Scientific Advisor to GeneLink, Dr. Kasten is intimately familiar with high-level genetics and personalized medicine.

A public company veteran, Dr. Kasten is a former Director and CEO of SIGA Technologies Inc. (SIGA:NASDAQ). Currently he is Chairman of the Board of Directors of the publicly traded biotechnology research and pharmaceutical development company, Cleveland BioLabs, Inc. (CBLI:NASDAQ).

Dr. Kasten commented, "Through DNA SNP (single nucleotide polymorphism) analysis, GeneLink can identify an individual’s particular genetic variants and has developed proprietary systems to create highly customized, unique skincare and nutritional products." He added that "genomic technology has evolved to enable personalization of products for the sophisticated consumer market."

CEO, Monte Taylor remarked, "We anticipate that Dr. Kasten’s vision and experience in the operations and governance of public companies will facilitate the continued development of corporate partnerships and strategic relationships that will further accelerate GeneLink’s future growth. With his integral knowledge of GeneLink’s technology, management team, and its strategic direction, Dr. Kasten is ideally suited to guide GeneLink’s scientific development."

About GeneLink Inc.
GeneLink is a biosciences company that creates genetic tests as the basis for personalized health, beauty, and wellness applications. Its patented DNA assessments provide information that enables the customization of skincare products, nutritional products, and health maintenance regimens that can be personalized to meet the individual consumer's need. GeneLink markets and licenses its products to the $100 Billion, cosmetic, nutritional supplement, and health care industries. For more information visit www.genelink.info and www.dermagenetics.com

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties.  Actual results could differ materially from those expressed in any forward-looking statement.  GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.